• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Subsense Emerges from Stealth with $17M to Develop Non-Surgical Brain-Computer Interface

by Fred Pennic 02/18/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Subsense, Inc., a pioneering neurotechnology company announced its official launch and the closing of a $17 million seed funding round led by Golden Falcon Capital. 

– The company is developing a groundbreaking non-surgical, nanoparticle-based Brain-Computer Interface (BCI) with the potential to transform the treatment of neurological conditions.

Nanoparticle-Based Technology Aims to Enhance Treatment of Neurological Conditions

Subsense is co-founded by Tetiana Aleksandrova, a neurotechnology entrepreneur with a passion for developing innovative solutions for brain health and Artem Sokolov, a serial entrepreneur and early investor in successful companies like Asana, SoFi, and Coursera.Subsense’s innovative technology utilizes nanoparticles to establish a bidirectional connection between the brain and external devices. This approach allows for targeted neural stimulation and precise monitoring, opening up new possibilities for treating a wide range of neurological disorders.

“Brain-computer interfacing promises to unlock limitless human potential, but innovation has been held back by a lack of effective non-surgical approaches,” said Tetiana Aleksandrova, Subsense’s Chief Executive Officer. “By delivering nanoparticles that bind with receptors in the brain, Subsense can achieve more extensive connectivity with a far gentler approach.”

Collaborating with Leading Research Institutions

Subsense is collaborating with a consortium of leading neurological research institutions, including UC Santa Cruz and ETH Zurich, to accelerate the development and validation of its technology.

Targeting Neurological Conditions

Subsense’s initial focus is on developing therapies for neurological conditions such as:

  • Parkinson’s disease
  • Alzheimer’s disease
  • Epilepsy
  • Depression
  • Stroke
  • Chronic pain

Expanding the Possibilities of Brain-Computer Interfaces

Beyond therapeutic applications, Subsense is also exploring more expansive possibilities for its technology, including:

  • Sensorimotor recovery: Restoring vision, hearing, and movement.
  • Inner speech decoding: Translating thoughts into words.
  • AI integration: Merging the human brain with artificial neural networks.
  • External memory: Creating a backup and extension of human memory.
  • Mental health regulation: Monitoring and controlling emotions and mood.
  • Appetite control: Managing hunger and satiety signals.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |